Rallis India Aims to Boost Exports and Contract Manufacturing Through Specialty Crop-Care Expansion
Rallis India Limited plans to scale up exports and Contract Research and Manufacturing Services (CRAMS) by expanding its specialty crop-care segment. The company is shifting its product mix towards high-value agri-inputs and biologicals to enhance margins. Despite a 7.22% YoY decrease in revenue, net profit increased by 4.08% in Q2 FY26. B2B revenue grew by 14% YoY, with exports up 33%. Eight new products were launched in H1 FY26, strengthening the company's portfolio in herbicides and fungicides. The company has also resumed biostimulant production in-house.

*this image is generated using AI for illustrative purposes only.
Rallis India Limited , a subsidiary of Tata Chemicals Limited, has announced plans to scale up its exports and Contract Research and Manufacturing Services (CRAMS) operations by expanding its specialty crop-care segment. The company aims to enhance its margins by shifting its product mix towards high-value agri-inputs and biologicals.
Export and CRAMS Growth Strategy
Rallis India intends to leverage its expertise in crop protection to capture a larger share of the global market. The company's focus on specialty crop-care products is expected to drive growth in both exports and contract manufacturing services. This strategic move aligns with the increasing global demand for advanced agricultural solutions.
Shift Towards High-Value Products
The company's strategy involves a deliberate shift in its product portfolio towards high-value agri-inputs and biologicals. This transition is expected to improve profit margins and strengthen Rallis India's position in the competitive agricultural inputs market.
Financial Performance
According to the company's recent financial results:
Metric | Q2 FY26 | Q2 FY25 | YoY Change |
---|---|---|---|
Revenue from Operations | 861.00 | 928.00 | -7.22% |
Net Profit | 102.00 | 98.00 | 4.08% |
EBITDA | 154.00 | 166.00 | -7.23% |
Despite a challenging quarter due to erratic rainfall affecting field activities, Rallis India managed to improve its net profit. The company's PAT margin improved by 120 basis points to 11.8% in Q2 FY26.
B2B and Export Performance
The company's B2B business, including exports, showed strong growth:
- B2B Revenue: Increased by 14% year-on-year in Q2 FY26
- Exports: Registered a growth of 33% driven by higher volumes in key molecules
This performance underscores the potential of Rallis India's export-oriented strategy.
Product Portfolio Expansion
Rallis India continues to strengthen its product offerings:
- Eight new products launched in H1 FY26
- Recent launches include Penflor, Allato, Deeweed, and Dodrio
- Expanded presence in herbicides and fungicides segments
The company has also resumed biostimulant sales through in-house production, enhancing its footprint in sustainable crop solutions.
Outlook
Dr. Gyanendra Shukla, Managing Director & CEO of Rallis India Limited, commented on the company's performance and strategy: "Despite challenging weather conditions, our profitability remained stable, supported by export momentum and prudent cost management. Our focus on expanding specialty crop-care and high-value agri-inputs is expected to drive growth in exports and contract manufacturing services."
As Rallis India continues to execute its strategy of expanding into specialty crop-care and high-value products, the company appears well-positioned to capitalize on global agricultural trends and enhance its market presence in the exports and contract manufacturing segments.
Historical Stock Returns for Rallis
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-3.13% | -6.29% | -16.18% | +26.13% | -22.74% | +4.39% |